Your session is about to expire
← Back to Search
RAD001 + PKC412 for Acute Myeloid Leukemia
Study Summary
This trial will study the safety and efficacy of the combination of RAD001 and PKC412 in subjects with relapsed or refractory solid tumors or hematologic malignancies.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been diagnosed with acute promyelocytic leukemia.I had a bone marrow or stem cell transplant less than 2 months ago.I do not have severe health or mental conditions that could stop me from completing the study.I currently have an infection that is not under control.I have high cholesterol or triglycerides despite taking medication.I can take care of myself but cannot do heavy physical work.I always follow my medical treatments as prescribed.I am on long-term steroids or other drugs that weaken my immune system.I have not had any live vaccines in the week before or during the study.I have not had any cancer except for certain skin or cervical cancers in the last 5 years.I don't expect to need treatment to reduce my blood cell count within a month, except for hydroxyurea.I have a stomach or intestine problem that affects how my body absorbs medication.My blood cancer diagnosis is confirmed and standard treatments haven't worked or aren't suitable for me.I am not pregnant, breastfeeding, and if capable of childbearing, I use effective contraception.I have tested positive for HIV.
- Group 1: Only one arm on this study.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has this therapeutic intervention been given the green light by the Food and Drug Administration?
"Due to the paucity of data supporting efficacy and safety, this treatment was assigned a score of 1 on our team's scale. This marks it as being an early-phase clinical trial."
Are there opportunities to join this experiment currently available?
"According to clinicaltrials.gov, this particular research project is no longer searching for participants, as it was first posted in 2009 and last updated in 2023. However, there are 859 other trials currently enrolling patients at this time."
Has anything like this research endeavor been attempted before?
"This treatment has been under the microscope since 2008, when Novartis Pharmaceuticals organized a pilot study of 717 participants. After Phase 3 drug approval was granted in response to this initial trial, 95 active studies for it have appeared across 1208 cities and 45 countries."
What is the current scope of enrollment for this research endeavor?
"Sadly, this research is no longer recruiting. It was initially listed on 1/1/2009 and last modified on 2/6/2023. If you seek an alternate trial, there are currently 764 studies for myelodysplastic syndrome patients actively looking for volunteers as well as 95 trials searching for participants related to this particular treatment."
What customary applications does this therapy encompass?
"This treatment is suitable for organ transplant rejection, specifically liver and kidney transplants, as well as Waldenstrom Macroglobulinemia and lung conditions."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger